Correction to: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy

Correction to: BMC Cancer 24, 797 (2024)

https://doi.org/10.1186/s12885-024-12564-4

Following publication of the original article [1], the author reported a typographical error in the Results section, where the value “222.5” should read “22.5,” and that Figs. 2 and 3 must be swapped. The image currently presented as Fig. 2 corresponds to the legend and content intended for Fig. 3, and vice versa.

Fig. 2.

Change of EBV load during treatment and response to immunotherapy. A. Waterfall plot of change from baseline in tumor size for patients with nasopharyngeal carcinoma. B. Change from baseline in EBV viral load for patients with PD and PR. C. OS curve of patients with EBV response vs. those with EBV progression. D. Swimmer plot that shows time to initial EBV response/progression and RECIST response/progression in PR and PD patients. RECIST, Response Evaluation Criteria in Solid Tumors; PD, progression disease; PR, partial remission; SD, stable disease; EBV, Epstein-Barr virus; OS, overall survival

Fig. 3.

EBV and RECIST assessment of 1 PR and 1 PD patients. A. Tumor size and plasma EBV load change over time in a PD patient. EBV load was on log10 scale. B. Tumor size and plasma EBV load change over time in a PR patient. EBV load was on log10 scale. EBV: Epstein-Barr virus; RECIST: Response Evaluation Criteria in Solid Tumors; PD: progression disease; PR: partial remission

1. Typographical error in Results section.

   • Original sentence:
     “EBV responders (N = 23) had significantly improved OS (log-rank p = 0.004, HR = 0.351 [95% CI: 0.171–0.720], median 222.5 vs. 11.9 months) compared to the EBV progression patients (N = 33) (Fig. 2C, Figure S2A).”
   • Corrected sentence:
     “EBV responders (N = 23) had significantly improved OS (log-rank p = 0.004, HR = 0.351 [95% CI: 0.171–0.720], median 22.5 vs. 11.9 months) compared to the EBV progression patients (N = 33) (Fig. 2C, Figure S2A).”

2. Figures 2 and 3 published in the wrong positions (need to be exchanged)

Incorrect Fig. 2

Fig. 2.

Change of EBV load during treatment and response to immunotherapy. A. Waterfall plot of change from baseline in tumor size for patients with nasopharyngeal carcinoma. B. Change from baseline in EBV viral load for patients with PD and PR. C. OS curve of patients with EBV response vs. those with EBV progression. D. Swimmer plot that shows time to initial EBV response/progression and RECIST response/progression in PR and PD patients. RECIST, Response Evaluation Criteria in Solid Tumors; PD, progression disease; PR, partial remission; SD, stable disease; EBV, Epstein-Barr virus; OS, overall survival

Correct Fig. 2

Incorrect Fig. 3

Correct Fig. 3

Fig. 3.

EBV and RECIST assessment of 1 PR and 1 PD patients. A. Tumor size and plasma EBV load change over time in a PD patient. EBV load was on log10 scale. B. Tumor size and plasma EBV load change over time in a PR patient. EBV load was on log10 scale. EBV: Epstein-Barr virus; RECIST: Response Evaluation Criteria in Solid Tumors; PD: progression disease; PR: partial remission